Choice Institutional Equities has maintained a 'BUY' rating on Park Medi World, setting a target price of Rs 350. The positive outlook is driven by the company’s strong quarterly performance and long-term goal of reaching 10,000 beds by FY33. Investors should note that while revenue is rising, the company faces short-term margin pressure due to the costs of opening new hospital facilities.
Choice Institutional Equities has reaffirmed its positive stance on Park Medi World, setting a target price of Rs 350 for the stock. This update comes as the hospital chain continues to expand its footprint across India, aiming to scale its operations to 10,000 beds by the 2033 fiscal year.
The company’s recent financial results reflect its ongoing growth. For the first quarter of the 2027 fiscal year, Park Medi World reported revenue of Rs 475.71 crore, which is a 19.3% increase compared to the same period last year. Profit after tax also showed strong momentum, rising by 35.2% to Rs 88.59 crore. The stock has recently been trading in the range of Rs 290 to Rs 294, reflecting market reaction to these earnings and future growth plans.
While top-line growth remains strong, the company is dealing with some pressure on its profit margins. The EBITDA margin for the quarter was 26.51%, representing a dip of 115 basis points compared to the previous quarter. According to company disclosures, this decline is primarily linked to the ramp-up costs associated with the new hospital facility in Panchkula. In the hospital business, new units typically incur fixed operational costs before they reach optimal patient occupancy, which can temporarily weigh on margins.
Park Medi World’s strategy relies on a cluster-based approach, where it builds multiple hospitals in specific geographic regions to share management and medical resources. This allows for better operational efficiency once a cluster matures. However, this model is capital-intensive, requiring significant upfront investment.
Investors tracking the company should be aware of several operational risks. The primary challenge is the execution risk associated with such an aggressive expansion. Building and filling hospitals with patients takes time, and any delays in construction or a slower-than-expected increase in patient numbers could impact future earnings. Additionally, the healthcare sector remains sensitive to regulatory changes, such as potential government price capping on medical services, which could affect the company’s pricing power.
The most important monitorable for investors in the coming quarters will be how effectively the company ramps up the utilization of its new facilities, including the Panchkula unit. Maintaining steady profit margins while continuing the expansion will be a key indicator of the company’s ability to turn its long-term bed-capacity targets into sustainable financial growth.